In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target

Shohei Murakami, Vilma Barroca, Leïla Perié, Anne Bravard, Jacqueline Bernardino-Sgherri, Amandine Tisserand, Caroline Devanand, Valérie Edmond, Aurélie Magniez, Sabrina Tenreira Bento, Claire Torres, Florence Pasquier, Isabelle Plo, William Vainchenker, Jean Luc Villeval, Paul Henri Roméo, Daniel Lewandowski

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    Current murine models of myeloproliferative neoplasms (MPNs) cannot examine how MPNs progress from a single bone marrow source to the entire hematopoietic system. Thus, using transplantation of knock-in JAK2V617F hematopoietic cells into a single irradiated leg, we show development of polycythemia vera (PV) from a single anatomic site in immunocompetent mice. Barcode experiments reveal that grafted JAK2V617F stem/progenitor cells migrate from the irradiated leg to nonirradiated organs such as the contralateral leg and spleen, which is strictly required for development of PV. Mutant cells colonizing the nonirradiated leg efficiently induce PV in nonconditioned recipient mice and contain JAK2V617F hematopoietic stem/progenitor cells that express high levels of carbonic anhydrase 1 (CA1), a peculiar feature also found in CD34+ cells from patients with PV. Finally, genetic and pharmacologic inhibition of CA1 efficiently suppresses PV development and progression in mice and decreases PV patients’ erythroid progenitors, strengthening CA1 as a potent therapeutic target for PV.

    Original languageEnglish
    Pages (from-to)285-297
    Number of pages13
    JournalBlood Cancer Discovery
    Volume3
    Issue number4
    DOIs
    Publication statusPublished - 1 Jul 2022

    Cite this